Juno Therapeutics, Inc. (NASDAQ:JUNO) Shares Bought by Parametric Portfolio Associates LLC

Parametric Portfolio Associates LLC boosted its position in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 88.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,826 shares of the biopharmaceutical company’s stock after buying an additional 18,713 shares during the period. Parametric Portfolio Associates LLC’s holdings in Juno Therapeutics were worth $884,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Guggenheim Capital LLC boosted its stake in Juno Therapeutics by 11.9% in the fourth quarter. Guggenheim Capital LLC now owns 146,738 shares of the biopharmaceutical company’s stock worth $2,766,000 after buying an additional 15,588 shares in the last quarter. Norges Bank bought a new stake in Juno Therapeutics during the fourth quarter worth about $13,993,000. Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the first quarter worth about $200,000. Creative Planning boosted its stake in Juno Therapeutics by 248.8% in the first quarter. Creative Planning now owns 48,016 shares of the biopharmaceutical company’s stock worth $1,065,000 after buying an additional 34,250 shares in the last quarter. Finally, Opus Point Partners Management LLC boosted its stake in Juno Therapeutics by 65.9% in the fourth quarter. Opus Point Partners Management LLC now owns 11,478 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 4,560 shares in the last quarter. Hedge funds and other institutional investors own 65.03% of the company’s stock.

Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) traded down 0.26% on Friday, reaching $26.99. 788,677 shares of the company’s stock were exchanged. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $34.35. The company has a 50 day moving average price of $28.75 and a 200 day moving average price of $24.87. The firm’s market cap is $2.83 billion.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by $0.24. The firm had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $15.59 million. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm’s revenue was down 22.8% on a year-over-year basis. During the same period last year, the company earned ($0.64) earnings per share. Analysts expect that Juno Therapeutics, Inc. will post ($3.13) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/juno-therapeutics-inc-nasdaqjuno-stake-boosted-by-parametric-portfolio-associates-llc-updated-updated-updated.html.

A number of analysts have recently issued reports on the stock. Vetr upgraded shares of Juno Therapeutics to a “buy” rating in a research note on Tuesday, May 23rd. Wedbush reiterated a “neutral” rating and issued a $24.00 price objective on shares of Juno Therapeutics in a research note on Tuesday, June 6th. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. BidaskClub upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Finally, Morgan Stanley dropped their price target on shares of Juno Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a research report on Monday, May 8th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. Juno Therapeutics presently has an average rating of “Hold” and a consensus price target of $30.63.

In related news, Director Anthony B. Evnin bought 9,000 shares of the business’s stock in a transaction dated Tuesday, June 20th. The shares were purchased at an average price of $24.40 per share, with a total value of $219,600.00. Following the transaction, the director now owns 66,301 shares in the company, valued at approximately $1,617,744.40. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the transaction, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. Insiders have sold a total of 8,053,500 shares of company stock worth $217,594,440 over the last ninety days. Insiders own 15.26% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit